$CRXTW News
Last published 4y ago
- 4y agoCRXTCRXTWClarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce ReductionGlobeNewswireSecond quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 4
- 4y agoCRXTCRXTWClarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)GlobeNewswireJATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Hol
- 4y agoCRXTCRXTWClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual MeetingGlobeNewswireJATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings,
- 4y agoCRXTCRXTWClarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)GlobeNewswireJATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA's Orange Book, which would bring the total nu
- 4y agoCRXTCRXTWClarus Therapeutics Reports First Quarter 2022 Financial and Operating ResultsGlobeNewswireFirst quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year Conference call and webcast today at 5:15 p.m. ET
- 4y agoCRXTCRXTWClarus Therapeutics to Report First Quarter 2022 Financial and Operating ResultsGlobeNewswireNORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and w
- 4y agoCRXTCRXTWClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory MastitisGlobeNewswireInitial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022 Initiation of Phase 2 clinical trial for CLAR
- 4y agoCRXTCRXTWClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual MeetingGlobeNewswireJATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., May 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, In
- 4y agoCRXTCRXTWClarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)GlobeNewswireJATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be listed in FDA's Orange Book, bringing the total num
- 4y agoCRXTCRXTWClarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public OfferingGlobeNewswireNORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and w
- 4y agoCRXTCRXTWClarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public OfferingGlobeNewswireNORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and w
- 4y agoCRXTCRXTWClarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual MeetingGlobeNewswireJATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., April 19, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, I
- 4y agoCRXTCRXTWClarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating ResultsGlobeNewswire2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% y
- 4y agoCRXTCRXTWClarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating ResultsGlobeNewswireNORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and
- 4y agoCRXTCRXTWClarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney DiseaseGlobeNewswireJATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce results from the trial in the first half of 2023
- 4y agoCRXTCRXTWClarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare ConferenceGlobeNewswireNORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and w
- 4y agoCRXTCRXTWClarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to PatientsGlobeNewswireJATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions New offerings underscore Clarus' continued commitment to providing so
- 4y agoCRXTCRXTWClarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development OfficerGlobeNewswireDr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Cl
- 4y agoCRXTCRXTWClarus Therapeutics Announces Closing of Approximately $15 Million Private PlacementGlobeNewswireProceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing
- 4y agoCRXTCRXTWClarus Therapeutics Announces $15 Million Private PlacementGlobeNewswireProceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing
- 4y agoCRXTCRXTWClarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)GlobeNewswireJATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list these patents in FDA's Orange Book, which would br
- 4y agoCRXTCRXTWClarus Therapeutics Reports Third Quarter 2021 Financial and Operating ResultsGlobeNewswireThird quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK,
- 4y agoCRXTCRXTWClarus Therapeutics to Report Third Quarter 2021 Financial and Operating ResultsGlobeNewswireNORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and
- 5y agoCRXTCRXTWClarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)GlobeNewswireJATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Upon issuance, Clarus plans to list these
- 5y agoCRXTCRXTWClarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNAGlobeNewswireJATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., Oct. 14, 2021 (G
- 5y agoCRXTCRXTWClarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewswireNORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, tod
- 5y agoCRXTCRXTWClarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) DeficienciesGlobeNewswireAgreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases An estimat
- 5y agoCRXTCRXTWClarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGlobeNewswireNORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and